Law360, New York (August 27, 2012, 12:48 PM EDT) -- On Aug. 8, 2012, the U.S. Department of Justice and the U.S. Securities and Exchange Commission announced agreements with the drug manufacturer Pfizer Inc. to settle allegations that a Pfizer subsidiary had paid bribes to non-U.S. doctors and health care system personnel in exchange for prescribing Pfizer products.
Pfizer is a global pharmaceutical and consumer product company headquartered in New York. It is listed on the New York Stock Exchange. The company’s activities were alleged to violate the U.S. Foreign Corrupt Practices Act.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.